{"id":"W1980810683","doi":"10.1007/s11523-007-0042-9","title":"Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study","year":2007,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ste. Anne's Hospital","funders":"National Cancer Institute; World Health Organization","keywords":"Docetaxel; Medicine; Gefitinib; Internal medicine; Lung cancer; Chemotherapy; Oncology; Combination therapy; Adverse effect; Rash; Cancer; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005291632,0.0002342474,0.0008643102,0.0002229526,0.0001295597,0.000006746282,0.00006536022,0.00009821825,0.0001727428],"category_scores_gemma":[0.0000222326,0.0001516705,0.00006875884,0.0003079906,0.00007640886,0.00007661715,0.00001113805,0.0001795068,9.733042e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004611395,"about_ca_system_score_gemma":0.0007000841,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002129518,"about_ca_topic_score_gemma":0.00277845,"domain_scores_codex":[0.9986129,0.00007200992,0.0004309144,0.0003626129,0.0001411918,0.0003803176],"domain_scores_gemma":[0.9988188,0.0003398481,0.0002648326,0.000185219,0.0002751122,0.0001161475],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8425724,0.0346819,0.01902081,0.0002301801,0.002012602,0.0004741406,0.02389068,0.0004887555,0.01055907,0.0001569265,0.0003802418,0.0655323],"study_design_scores_gemma":[0.9486617,0.03443628,0.003401035,0.00007282327,0.000794697,0.00001786468,0.001883077,0.001067884,0.006155689,0.00004239933,0.003240324,0.0002261739],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807699,0.001248539,0.005572032,0.0006347677,0.000147837,0.009187584,0.00003958636,0.00005602288,0.002343761],"genre_scores_gemma":[0.9885989,0.0001178749,0.006316091,0.0006186607,0.00007964971,0.002652295,0.000212395,0.00004307291,0.001361058],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1060894,"threshold_uncertainty_score":0.6184942,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0137413535267044,"score_gpt":0.3733654310320024,"score_spread":0.359624077505298,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}